TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8641230

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) at a target dosage of 800 mg/day (400 mg twice daily)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 1523351

Group type: EXPERIMENTAL
Intervention: 7 + 3 chemotherapy protocol
Number of subjects: 76

Group type: COMPARATOR
Intervention: TADOP chemotherapy protocol
Number of subjects: 76
Study: 7100823

Group type: EXPERIMENTAL
Intervention: Amoxycillin, 50 mg/kg twice daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pivampicillin, 50 mg/kg twice daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intramuscular ampicillin
Number of subjects: 14
Study: 31070690

Group type: EXPERIMENTAL
Intervention: Sorafenib plus HAIC (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2 on day 1, and fluorouracil infusion 2400 mg/m2 for 46 hours, every 3 weeks)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 247
Study: 28270335

Group type: EXPERIMENTAL
Intervention: Web-based CBT intervention (Thinking Forward)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Primary care treatment as usual (TAU)
Number of subjects: 162
Study: 26859106

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study: 24219891

Group type: EXPERIMENTAL
Intervention: High-fructose diet (150 g per day for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-glucose diet (150 g per day for 4 weeks)
Number of subjects: 20
Study: 17943364

Group type: EXPERIMENTAL
Intervention: Transanal endoscopic microsurgery (TEM)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection (LR) via total mesorectal excision
Number of subjects: 70
Study: 15470337

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11723973

Group type: EXPERIMENTAL
Intervention: Training group (completed a toy maze three times a day for 7 days with their left hands)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (did not train)
Number of subjects: 48
Study: 9399010

Group type: EXPERIMENTAL
Intervention: Lanepitant 30 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Lanepitant 80 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Lanepitant 240 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 7895898

Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 10
Study: 3300274

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (200 mg tid)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 11245765

Group type: EXPERIMENTAL
Intervention: Isometric abduction of the arm (two trials per side)
Number of subjects: 24
Study: 30628519

Group type: EXPERIMENTAL
Intervention: sequential naïve pinhole bone scan (nPBS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: sequential gamma correction pinhole bone scan (GCPBS)
Number of subjects: 10
Study: 29543506

Group type: EXPERIMENTAL
Intervention: Lidcombe Program treatment
Number of subjects: 11
Study: 26606167

Group type: EXPERIMENTAL
Intervention: Predictive model for delayed wound healing using machine learning methods; developed on training data available in the first week of care.
Number of subjects: 59953

Group type: EXPERIMENTAL
Intervention: Early prediction of delayed healing wounds
Number of subjects: 59953
Study: 23780825

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) for 24 weeks
Number of subjects: 66
Study: 22858864

Group type: EXPERIMENTAL
Intervention: Social anxiety disorder (SAD) participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 0
Study: 20331676

Group type: EXPERIMENTAL
Intervention: Early educational intervention
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Risk factors
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Home environment
Number of subjects: 139
Study: 17683491

Group type: EXPERIMENTAL
Intervention: Mosapride citrate 10 mg 1 hour before CE examination
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no preparation)
Number of subjects: 60
Study: 16143696

Group type: EXPERIMENTAL
Intervention: Bisoprolol (target dose 10 mg QD)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Enalapril (target dose 10 mg BID)
Number of subjects: 1010
Study: 12374439

Group type: EXPERIMENTAL
Intervention: Participants who imagined being with a group at Time 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants who imagined being alone with one other person at Time 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants who imagined the presence of others
Number of subjects: 0
Study: 10407709

Group type: EXPERIMENTAL
Intervention: Reminder letter + phone call (group 3)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Reminder letter (group 2)
Number of subjects: 298

Group type: COMPARATOR
Intervention: No intervention (control group 1)
Number of subjects: 298
Study: 8624229

Group type: EXPERIMENTAL
Intervention: Tartar‐Control Crest (3.3% pyrophosphate)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Regular Crest (without pyrophosphate)
Number of subjects: 163
Study: 2208231

Group type: EXPERIMENTAL
Intervention: Nifedipine, 60 mg per day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Diltiazem, 270 mg per day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Combination of 30 mg nifedipine per day with 180 mg diltiazem per day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Combination of 60 mg nifedipine per day with 270 mg diltiazem per day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 25
Study: 7191306

Group type: EXPERIMENTAL
Intervention: Acemetacin (t.i.d. for 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indometacin (equimolar doses, t.i.d. for 10 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acemetacin (single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indometacin (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acemetacin and Indometacin (after multiple application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acemetacin (after multiple application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indometacin (after multiple application)
Number of subjects: 0
Study: 31088438

Group type: EXPERIMENTAL
Intervention: Food4toddlers eHealth intervention (6-month duration)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 404
Study: 28104418

Group type: EXPERIMENTAL
Intervention: Ahmed implant
Number of subjects: 514

Group type: COMPARATOR
Intervention: Baerveldt implant
Number of subjects: 514
Study: 25835440

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 1503

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 1503

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 1503

Group type: EXPERIMENTAL
Intervention: Patients with events
Number of subjects: 1503
Study: 23683451

Group type: EXPERIMENTAL
Intervention: Narcotrend monitor
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard group (control)
Number of subjects: 80
Study: 22843282

Group type: EXPERIMENTAL
Intervention: Tafamidis 20 mg QD
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 19423108

Group type: EXPERIMENTAL
Intervention: Pravastatin (10-20mg daily)
Number of subjects: 7196

Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin
Number of subjects: 7196

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 7196
Study: 17332205

Group type: EXPERIMENTAL
Intervention: Parenting-skills training plus intensive lifestyle education
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Parenting-skills training alone
Number of subjects: 111

Group type: COMPARATOR
Intervention: Wait-listed control
Number of subjects: 111
Study: 15683158

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (midwife visits during pregnancy and one after delivery)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (standard written information about health risks)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Intervention group (after controlling for socio-demographic characteristics)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (after controlling for socio-demographic characteristics)
Number of subjects: 149
Study: 11161243

Group type: EXPERIMENTAL
Intervention: Locus-specific amplification
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Group-specific amplification
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sequence-specific amplification
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Locus-specific amplification (clinical samples)
Number of subjects: 59
Study: 9700992

Group type: EXPERIMENTAL
Intervention: Aspirin 990 mg/day plus dipyridamole 225 mg/day
Number of subjects: 1306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1306
Study: 7978695

Group type: EXPERIMENTAL
Intervention: 5 mg folic acid weekly
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 27.5 mg folic acid weekly
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (both doses)
Number of subjects: 79
Study: 2691812

Group type: EXPERIMENTAL
Intervention: Fish oil and exercise (FE), N = 7, 50 ml of oil daily and 3 d.wk‐1 of aerobic exercise
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fish oil (F), N = 7, 50 ml of oil daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Corn oil (CN), N = 10, 50 ml of oil daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (C), N = 10
Number of subjects: 34
Study: 29948869

Group type: EXPERIMENTAL
Intervention: Acetaminophen iv (n = 63)
Number of subjects: 127
Study: 28017186

Group type: EXPERIMENTAL
Intervention: 25mg CAR
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 50mg CAR
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 106
Study: 26636279

Group type: EXPERIMENTAL
Intervention: 30 Hz WBV training
Number of subjects: 22

Group type: COMPARATOR
Intervention: 50 Hz WBV training
Number of subjects: 22
Study: 24565346

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia and femoral nerve block (FNB)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Spinal anesthesia (GA)
Number of subjects: 53
Study: 21676083

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol tablets (25 µg, 4-hourly, max 5 doses)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Vaginal dinoprostone (PGE2) gel (0.5 mg, 6-hourly, max 2 doses)
Number of subjects: 212
Study: 18458358

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) loading (5 g dicreatine citrate plus 10 g of flavored fructose powder per packet, 20 g/d for 5 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (Pl; 10 g of flavored fructose powder per packet)
Number of subjects: 16
Study: 16801033

Group type: EXPERIMENTAL
Intervention: Nocturnal nasal positive pressure ventilation (NNPPV) for 6 months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study: 12710224

Group type: EXPERIMENTAL
Intervention: Self-rated olfactory ability
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Younger patients
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Older patients
Number of subjects: 203
Study: 11063477

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formula (low cholesterol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formula high in linoleate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet providing <22% of energy from fat and low in animal fats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wasting (percentage weight-for-height <2 SDs)
Number of subjects: 0
Study: 9138958

Group type: EXPERIMENTAL
Intervention: Transvaginal color Doppler assessment
Number of subjects: 790
Study: 8093548

Group type: EXPERIMENTAL
Intervention: Propranolol-LA
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3512226

Group type: EXPERIMENTAL
Intervention: Nonretard isosorbide dinitrate, 20 and 40 mg six times daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Crossover double-blind randomized study
Number of subjects: 10
Study: 31746542

Group type: EXPERIMENTAL
Intervention: 1% tetracaine hydrochloride injection pure solution aerosol inhalation combined with oral 5 mL of dyclonine hydrochloride mucilage
Number of subjects: 523

Group type: COMPARATOR
Intervention: Diluted tetracaine hydrochloride injection (3 mL of 1% tetracaine hydrochloride injection + 3 mL of sterile water for injection) aerosol inhalation combined with oral 5 mL of dyclonine hydrochloride mucilage
Number of subjects: 523
Study: 31107843

Group type: EXPERIMENTAL
Intervention: FocusSpecs adjustable spectacles
Number of subjects: 86
Study: 28643436

Group type: EXPERIMENTAL
Intervention: Emotional awareness and expression training (EAET)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 106

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 106
Study: 26160211

Group type: EXPERIMENTAL
Intervention: Adjustable Velcro compression devices (AVCDs)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Inelastic bandages (IBs)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both compression devices
Number of subjects: 36
Study: 23388468

Group type: EXPERIMENTAL
Intervention: Self-monitoring of snack-eating behavior
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-monitoring of alcohol-drinking behavior
Number of subjects: 0
Study: 22098180

Group type: EXPERIMENTAL
Intervention: Behavioral Nutrition Intervention (B-NICE)
Number of subjects: 0
Study: 19726771

Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum (0.58 mg per injection)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum
Number of subjects: 308
Study: 18162014

Group type: EXPERIMENTAL
Intervention: Divalproex monotherapy (target dose level, 70‐90 ng/dL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 14609035

Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg bid for 4 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 10789569

Group type: EXPERIMENTAL
Intervention: Modified hemofiltration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (standard technique)
Number of subjects: 40
Study: 8851312

Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol hydrobromide (600 micrograms) during 3-minute UNDW inhalation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol hydrobromide (400 micrograms) during 1-minute UNDW inhalation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Inhaled oxitropium bromide (300 micrograms) during 3-minute UNDW inhalation
Number of subjects: 17
Study: 1505329

Group type: EXPERIMENTAL
Intervention: Modem group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 6418654

Group type: EXPERIMENTAL
Intervention: Balanced AA solution with 10% branched chain amino acids (BCAA)
Number of subjects: 3

Group type: COMPARATOR
Intervention: AA solution with 60% BCAA
Number of subjects: 3

Group type: COMPARATOR
Intervention: AA solution with 67% alanine
Number of subjects: 3
Study: 2412070

Group type: EXPERIMENTAL
Intervention: Ketanserin (selective S2-serotonergic receptor antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapies
Number of subjects: 0
Study: 30353303

Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy
Number of subjects: 331
Study: 27686343

Group type: EXPERIMENTAL
Intervention: Nitric oxide (20 ppm)
Number of subjects: 198
Study: 24527467

Group type: EXPERIMENTAL
Intervention: 2 µg dexmedetomidine added to 3 mL (15 mg) hyperbaric bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4 µg dexmedetomidine added to 3 mL (15 mg) hyperbaric bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5 mL saline added to 3 mL (15 mg) hyperbaric bupivacaine
Number of subjects: 60
Study: 21937481

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (LAmB) plus deferasirox (20 mg/kg/day for 14 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: LAmB plus placebo
Number of subjects: 20
Study: 20826626

Group type: EXPERIMENTAL
Intervention: 3 mg dihydrocapsiate/d
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 9 mg dihydrocapsiate/d
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Combined data from both dihydrocapsiate groups
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (0 mg dihydrocapsiate/d)
Number of subjects: 78
Study: 18379965

Group type: EXPERIMENTAL
Intervention: Multimodality therapy (including TUR, radiation, and chemotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative radiochemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radical cystectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Organ-preserving approach (including TUR and intravesical therapy)
Number of subjects: 0
Study: 15941630

Group type: EXPERIMENTAL
Intervention: E2/NETA (2mg of 17beta‐oestradiol combined with 1mg of norethisterone acetate)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5mg/day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no HRT)
Number of subjects: 75
Study: 12926839

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540
Study: 10947687

Group type: EXPERIMENTAL
Intervention: Single injection peribulbar block
Number of subjects: 51
Study: 8818756

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 1428467

Group type: EXPERIMENTAL
Intervention: Active agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active corticosteroids
Number of subjects: 0
Study: 6230034

Group type: EXPERIMENTAL
Intervention: Ipratropium (40 micrograms) and theophylline (oxtriphylline 400 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31205487

Group type: EXPERIMENTAL
Intervention: SPMC oral solution
Number of subjects: 901

Group type: COMPARATOR
Intervention: P/MC powder
Number of subjects: 901
Study: 30219444

Group type: EXPERIMENTAL
Intervention: Sound-bed music intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control condition (resting time)
Number of subjects: 48
Study: 26540079

Group type: EXPERIMENTAL
Intervention: Solution-Focused Therapy (SFT)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Short-Term Psychodynamic Psychotherapy (SPP)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Long-Term Psychodynamic Psychotherapy (LPP)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 326
Study: 25178112

Group type: COMPARATOR
Intervention: High-dose inhaled fluticasone propionate (FP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard-dose inhaled fluticasone propionate (FP)
Number of subjects: 40
Study: 22491567

Group type: EXPERIMENTAL
Intervention: Chlorhexidine‐gluconate (CHG) (4%) scrub
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chlorhexidine‐gluconate (CHG) (4%) spray
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Povidone‐iodine (PI) (10%) scrub
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Povidone‐iodine (PI) (10%) spray
Number of subjects: 40

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 40
Study: 20629810

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ
Number of subjects: 468
Study: 18313750

Group type: EXPERIMENTAL
Intervention: Feedback during practice interviews
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-interview feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 0
Study: 16326674

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% plus lornoxicam 8 mg (Group RL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 80
Study: 12357143

Group type: EXPERIMENTAL
Intervention: PaCO(2) at 20, 30, 40, 50, or 60 mmHg maintained for 45 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mild intraoperative hypercapnia (increased PaCO(2))
Number of subjects: 10
Study: 10224178

Group type: EXPERIMENTAL
Intervention: Literacy promoting intervention (bilingual children's book, bilingual handout, literacy-promoting guidance)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 135
Study: 9101851

Group type: EXPERIMENTAL
Intervention: Transanal microsurgery (TEM) for T1-carcinomas
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Transanal microsurgery (TEM) for adenomas
Number of subjects: 241

Group type: COMPARATOR
Intervention: Transanal microsurgery (TEM) and anterior resection (AR) for T1-carcinomas
Number of subjects: 241
Study: 1806490

Group type: EXPERIMENTAL
Intervention: Biosynthetic human growth hormone (hGH) 0.03 mg/kg subcutaneously 3 times a week for 12 months (6-18 months experimental period)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Biosynthetic human growth hormone (hGH)
Number of subjects: 45
Study: 6613689

Group type: EXPERIMENTAL
Intervention: 100 mg ascorbic acid daily for two weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 500 mg ascorbic acid daily
Number of subjects: 10